Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thioguanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioguanine SCHEMBL5977650 | 1.00 | PNP (0.57) | PNPALDH1A1HPGDXDHUSP2 | |
| Thioguanine SCHEMBL17515061 | 1.00 | PNP (0.57) | PNPALDH1A1HPGDXDHUSP2 | |
| Thioguanine SCHEMBL28286407 | 0.95 | PNP (0.55) | PNPALDH1A1HPGDXDHUSP2 | |
| Thioguanine SCHEMBL28527269 | 0.94 | PNP (0.54) | PNPALDH1A1HPGDXDHUSP2 | |
| Thioguanine SCHEMBL28184589 | 0.93 | PNP (0.53) | PNPALDH1A1HPGDXDHUSP2 | |
| Thioguanine SCHEMBL5977636 | 0.91 | PNP (0.51) | PNPALDH1A1HPGDXDHUSP2 | |
| Thioguanine SCHEMBL3701 | 0.90 | PNP (0.62) | PNPALDH1A1HPGDXDHUSP2 | |
| Thioguanine SCHEMBL1176577 | 0.90 | PNP (0.62) | PNPALDH1A1HPGDXDHUSP2 | |
| Triphosphate SCHEMBL16180222 | 0.89 | PNP (0.49) | PNPALDH1A1HPGDXDHUSP2 | |
| Thioguanine SCHEMBL28385604 | 0.89 | PNP (0.61) | PNPALDH1A1HPGDXDHUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016027106-A1 | CELL ASSAY | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2016-02-25 | — | — | WO | claimed |
| EP-4190339-B1 | A MODULATABLE SWITCH FOR SELECTION OF DONOR MODIFIED CELLS | CSL BEHRING GENE THERAPY INC (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-119639883-A | SNP locus combination for thiopurine medicine bone marrow suppression risk prediction and application | 中山大学附属第一医院 | 2025-03-18 | — | — | CN | disclosed |
| US-20240024347-A1 | PRODRUGS OF 6-MERCAPTOPURINE | THE JOHNS HOPKINS UNIVERSTY | 2024-01-25 | — | — | US | disclosed |
| US-20230355674-A1 | DONOR T-CELLS WITH KILL SWITCH | CSL BEHRING LLC (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4190339-A1 | A MODULATABLE SWITCH FOR SELECTION OF DONOR MODIFIED CELLS | CSL Behring Gene Therapy, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4172335-A1 | DONOR T-CELLS WITH KILL SWITCH | CSL Behring LLC (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-115997015-A | Donor T cells with kill switch | 美国杰特贝林生物制品有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-3654994-B1 | A MODULATABLE SWITCH FOR SELECTION OF DONOR MODIFIED CELLS | CSL BEHRING GENE THERAPY INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220072046-A1 | MODULATABLE SWITCH FOR SELECTION OF DONOR MODIFIED CELLS | CSL BEHRING GENE THERAPY INC (US) | 2022-03-10 | — | — | US | disclosed |
| CN-110544517-A | Disease activity characterization method for personalized therapy management | NESTLE SA | 2019-12-06 | — | — | CN | disclosed |
| US-10426798-B2 | Modulatable switch for selection of donor modified cells | Calimmune, Inc. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190054119-A1 | MODULATABLE SWITCH FOR SELECTION OF DONOR MODIFIED CELLS | CALIMMUNE INC (US) | 2019-02-21 | — | — | US | disclosed |
| WO-2019018491-A1 | A MODULATABLE SWITCH FOR SELECTION OF DONOR MODIFIED CELLS | Calimmune, Inc. (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2016027106-A1 | CELL ASSAY | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2016-02-25 | — | — | WO | disclosed |
| CN-103502815-B | Assay for detecting autoantibodies to anti-TNF alpha drugs | Nestle Products Technical Assistance Co.,Ltd. (CH) | 2015-09-23 | — | — | CN | disclosed |
| WO-2014170712-A1 | RAC-1 INHIBITORS OR PI3K INHIBITORS FOR PREVENTING INTESTINAL BARRIER DYSFUNCTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-10-23 | — | — | WO | disclosed |
| CN-103502815-A | Assay for detecting autoantibodies to anti-TNF alpha drugs | NESTEC SA | 2014-01-08 | — | — | CN | disclosed |
| US-20050123937-A1 | Methods for the electrochemical detection of target compounds | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2005-06-09 | — | — | US | disclosed |
| WO-2004092708-A2 | METHODS FOR THE ELECTROCHEMICAL DETECTION OF TARGET COMPOUNDS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024347-A1 | PRODRUGS OF 6-MERCAPTOPURINE | TPMT, TYMP, MTAP | PNP 5/4885ALDH1A1 340/4885HPGD 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.